Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds

Eye strokes' that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says author

Patients taking Wegovy have nearly five times the risk of sudden sight loss of those on Ozempic, a large-scale study has found.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines such as semaglutide (sold as Wegovy, Ozempic and Rybelsus) and tirzepetide (sold as Mounjaro) help reduce blood sugar levels, slow digestion and reduce appetite, and have been linked to reduced risks of heart attack, fewer drug overdoses and other health benefits.